1. Introduction {#s0005}
===============

In the brain, iron is an abundant element mostly stored in ferritin clusters. It is essential for brain development and is involved in many biochemical processes, including myelin synthesis ([@bb0150], [@bb0280]). In several neurological disorders such as multiple sclerosis (MS), brain iron is dysregulated and often present around plaques as activated iron-laden macrophages ([@bb0220], [@bb0180]). Excessive free iron in the deep gray matter (GM) may induce (e.g. due to oligodendrocyte dysfunction) or amplify neurodegeneration through generation of reactive oxygen species ([@bb0125]).

Brain iron concentrations have long been known to increase with normal aging ([@bb0185], [@bb0175]). In most deep GM regions, the increase appears to slow down and level with age, while in the thalamus a reduction in iron concentration is often observed after mid-life. Also, sex differences have been reported ([@bb0035]), with men having higher brain iron loads. For years, many post-mortem and in vivo studies using iron-sensitive imaging techniques have described changes in brain iron homeostasis in an array of neurologic disorders ([@bb0150], [@bb0360]), including Alzheimer\'s disease ([@bb0195], [@bb0100], [@bb0010]), Parkinson\'s disease ([@bb0195], [@bb0105]), and MS ([@bb0110], [@bb0385], [@bb0175]).

Genetic variations in iron-regulating genes, e.g., H63A and C282Y variants of the human hemochromatosis (*HFE*) gene, can influence peripheral iron load ([@bb0090]). However, it remains unclear to what extent specific iron-regulating genes influence brain iron homeostasis, and whether there would be effects specific to neurological diseases. A recent R2\* study by Pirpamer et al. ([@bb0250]) did not observe iron regulatory gene effects (nor any effect of sex) on brain iron levels of healthy subjects. Another study, however, reported that healthy men carrying either the *HFE* or Transferrin C2 genetic variant did have increased caudal iron levels, as compared to non-carriers ([@bb0035]), suggesting that a genetic effect on brain iron may be sex dependent. Iron gene status may also be linked to the association between brain iron and cognition ([@bb0040]). In addition, the presence of common gene variants involved in iron metabolism and transport appear to influence the age of onset and disease severity, and are more prevalent in neurological diseases associated with iron dysregulation, such as Alzheimer\'s disease ([@bb0270], [@bb0225], [@bb0295]), amyotrophic lateral sclerosis ([@bb0355]), and Parkinson\'s disease ([@bb0120]). In two European MS studies, the frequency of *HFE* H63A and C282Y variants were comparable to controls. However, *HFE* C282Y mutant allele carriers did report earlier disease onset ([@bb0275]) and more rapid disability progression ([@bb0065]). An Australian study reported increased prevalence of the *HFE* C282Y mutation in MS (10.2% vs. controls: 6.7%) ([@bb0285]).

In MS, studies have shown that brain iron levels are disturbed especially in the deep GM ([@bb0020], [@bb0385], [@bb0325]), and around plaques ([@bb0110]). Several recent MRI studies have utilized the novel quantitative susceptibility mapping (QSM) technique in MS to investigate in vivo tissue changes ([@bb0380], [@bb0175]). QSM is an advanced MR imaging method ([@bb0265], [@bb0315]) allowing the measurement of subtle changes of the magnetic susceptibility, reflecting tissue concentrations of paramagnetic iron complexes ([@bb0210], [@bb0340]), but also calcium ([@bb0300], [@bb0095], [@bb0340]), and myelin ([@bb0305], [@bb0340], [@bb0145]). It is currently regarded as one of the most sensitive and specific techniques for studying tissue iron in vivo ([@bb0215], [@bb0345]).

To date, gene variants linked to iron regulation have not been investigated in the context of in vivo brain iron measurements in MS patients. As such, the present study investigated the effect of genetic variants linked to iron regulation in relation to deep GM tissue changes as measured by QSM in both healthy individuals and MS patients.

2. Methods {#s0010}
==========

2.1. Subjects {#s0015}
-------------

In this substudy of the cardiovascular, genetic and environmental study in MS ([@bb0200], [@bb0390]), healthy controls (HC) and MS patients were prospectively enrolled and group-matched by age and sex: 150 HC and 400 MS patients (relapsing-remitting \[RRMS\]: 261, progressive MS: 139). Subjects needed to have 3 T MRI examination with the sequences suitable for QSM and brain volumetry examination having been applied successfully, as well as genetic determination for iron-related gene variants. MS patients were included if they had a relapsing or progressive (secondary- or primary-progressive) disease course. Patients with a relapse and/or steroid treatment within 30 days prior to MRI were excluded. Additional exclusion criteria were: pregnancy, presence of pre-existing medical conditions known to be associated with brain pathology (e.g., cerebrovascular disease, positive history of alcohol dependence). MS patients were diagnosed using the revised McDonald criteria ([@bb0260]) and clinical disease severity was measured using the Expanded Disability Status Scale (EDSS) ([@bb0205]). HC were recruited from volunteers with a normal neurological examination and no history of neurologic disorders or chronic psychiatric disorders. The study was approved by the local Institutional Review Board at the University at Buffalo. Written informed consent was obtained from all participants.

2.2. Genotyping {#s0020}
---------------

Anti-coagulated peripheral blood was obtained by venipuncture for all participants. DNA was extracted from peripheral blood mononuclear cells preserved in TRI reagent (Molecular Research Center Inc., Cincinnati, OH, USA). A panel of candidate single nucleotide polymorphisms (SNPs) linked to iron regulation pathways were genotyped using the OpenArray platform (Applied Biosystems, Life Technologies, Foster City, CA). The genotyped polymorphisms were: rs1800562, rs1799945, and rs1049296. The SNP rs1800562 is found in the majority of cases with hemochromatosis (risk allele A: C282Y). The SNP rs1799945 is also a gene associated with hereditary hemochromatosis (risk allele G: H63D). rs1049296 is associated with transferrin (TF), the main iron transport protein (risk allele T: C2-subtype). The homozygous and heterozygous minor allele-containing genotypes (classified as 'carriers') were pooled for statistical comparison to the homozygous major allele genotype (classified as 'non-carriers').

2.3. MRI image acquisition {#s0025}
--------------------------

All participants were imaged with the same clinical 3 T GE Signa Excite HD 12.0 scanner (General Electric, Milwaukee, WI, USA) using an eight-channel head-and-neck coil. A detailed description of pulse sequences and image reconstruction steps has been reported previously ([@bb0175]). Briefly, acquired sequences included a 3D single-echo spoiled gradient recalled echo (GRE) sequence for QSM (512x192x64 matrix and a nominal resolution of 0.5 × 1 × 2 mm^3^ (FOV = 256 × 192 × 128 mm^3^), flip angle = 12°, TE/TR = 22 ms/40 ms, and bandwidth = 13.89 kHz) and a 3D T1-weighted (T1w) fast spoiled GRE sequence for the determination of brain volume measures (TE/TI/TR = 2.8/900/5.9 ms, flip angle = 10^o^, isotropic 1 mm resolution).

2.4. QSM {#s0030}
--------

QSM processing was performed by a fully automated pipeline with in-house developed MATLAB programs (2013b, The MathWorks, Natick, MA). Processing and susceptibility map reconstruction details were provided previously ([@bb0175]). Magnitude and phase GRE images were reconstructed offline on a 512 × 512 × 64 spatial matrix. *K*-space was zero-padded in phase-encode direction prior to the processing to achieve isotropic in-plane resolution. Distortions due to imaging gradient non-linearity were compensated ([@bb0255]). Phase images were unwrapped with a best-path algorithm ([@bb0005]), background-field corrected with V-SHARP ([@bb0305], [@bb0365]) (radius 5 mm; TSVD threshold 0.05), and converted to magnetic susceptibility maps using the HEIDI algorithm ([@bb0310]). Magnetic susceptibility maps were referenced (0 ppb) to the average susceptibility of the brain. This was done to minimize potential confounding bias from (unknown) disease-related susceptibility changes, e.g. due to demyelination, in a more localized anatomical reference region ([@bb0115], [@bb0335]), as well as limit the inter-subject variability resulting from an absolute reference susceptibility value. Magnetic susceptibility is reported in parts per billion (ppb).

2.5. Voxel-based analysis {#s0035}
-------------------------

We performed a voxel-based analysis (VBA) of the susceptibility maps to determine SNP and disease-related tissue alterations without prior assumptions about the location of the changes. To this end, susceptibility maps were normalized with the diffeomorphic Greedy-SyN transformation model (Advanced Normalization Tools; version 2.1; <http://stnava.github.io/ANTs>) to an in-house generated susceptibility brain template created from 90 subjects (30 HC, 30 RRMS, and 30 secondary progressive patients over a wide range of ages) with 1 mm^3^ isotropic voxel size ([@bb0190]).

After smoothing with a 1 mm Gaussian kernel, we performed voxel-wise statistical analysis via non-parametric permutation tests (FSL randomise ([@bb9500]); 5000 permutations) using age and sex as covariates to identify susceptibility differences between patient groups and their respective control groups. Both analyses with and without threshold-free cluster enhancement (TFCE) controlling for family-wise error (FWE) rate, were carried out at the p \< 0.05 level.

2.6. Deep gray matter segmentation {#s0040}
----------------------------------

Anatomical deep GM regions were segmented using FSL FIRST (<http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FIRST> ([@bb0240])) on 3D SPGR T~1~w images corrected for T~1~-hypointensity misclassification ([@bb0135]). Mean values of susceptibility were calculated in bilateral thalamus, caudate, putamen, and globus pallidus. To obtain the tissue volume of each region, volumes were normalized to the participants\' head volume as determined by the SIENAX-derived scaling factor (FMRIB SIENAX version 2.6) ([@bb9505]). Volumes are expressed in milliliters.

2.7. Statistical analysis {#s0045}
-------------------------

Analyses were carried using SPSS 24.0 (IBM, Armonk, NY) and R (3.2.1, R Foundation for Statistical Computing, Vienna, Austria). Normality of distributions was tested using Q-Q plots and the Shapiro-Wilk test. Baseline characteristics were compared using chi-squared and Student\'s *t*-test. Paired student\'s *t-*test was used to determine whether mean values of anatomical regions were different between left and right hemispheres. Outcome measures were averaged between left and right hemispheres in case no significant hemisphere effect was observed; otherwise analyses were carried out separately. Main effects of disease, MS course, age, sex and carrier status on magnetic susceptibility were analyzed using student *t-*test and Spearman\'s rank correlation analysis. Magnetic susceptibility and volume of the carriers and non-carrier groups were explored within the general linear model (GLM) framework between disease and MS course, with all models including age, age^2^, and sex terms. Analyses split by sex were adjusted for age. Because changes in susceptibility in MS could be driven by loss of tissue ([@bb0175]), post-hoc analyses corrected for the structural volume in question were carried out when a significant difference in magnetic susceptibility was observed. Clinical associations of genotypes were assessed with EDSS using the Mann-Whitney *U* test. Effect sizes were estimated with Cohen\'s *d*, α-level was set at 0.05, and significance levels are reported both as uncorrected (p \< 0.05) and corrected for multiple comparisons using false discovery rate (FDR; q-value \< 0.05) ([@bb0055]), in order to both maximize statistical power, minimize false negative findings, while also reporting stringent p-value correction.

3. Results {#s0050}
==========

3.1. Clinical, demographic and genotype characteristics {#s0055}
-------------------------------------------------------

The distribution of age and sex between control subjects (45.6 ± 12.9 years, 66% female) and MS patients (46.6 ± 10.5 years, 64% female) was highly similar (p = 0.400 and p = 0.662, respectively) ([Table 1](#t0005){ref-type="table"}). Among MS patients, the median EDSS score was 3.0 (IQR: 2.0--5.5), disease duration was 14.8 ± 10.7 years, and 65.3% had a relapsing disease course (RRMS).Table 1Clinical and demographic data.Table 1.HC\
n = 150Multiple sclerosis\
(n = 400)p-valueFemale, n (%)99 (66%)256 (64%)0.662Age45.6 (12.9)46.6 (10.5)[b](#tf0010){ref-type="table-fn"}0.400Relapsing-remitting MS, n (%)n/a261 (65%)n/aProgressive MS, n (%)n/a139 (35%)[c](#tf0015){ref-type="table-fn"}n/aEDSS, median ± IQRn/a3.0 (2.0--5.5)n/aDisease duration in yearsn/a14.8 ± 10.7n/aRelapses in the previous year, median ± IQRn/a0 ± (0--1)n/aAge of MS onset, mean (SD)n/a32.0 (9.8)n/aDisease modifying therapy, n (%) Non-therapyn/a113 (28%)n/a Interferonsn/a112 (28%) Glatiramer acetaten/a72 (18%) Natalizumabn/a49 (12%) Immunosuppressantn/a5 (1%) Combination therapyn/a4 (1%) Other/unknownn/a45 (11%)*HFE* rs1800562 A allele[a](#tf0005){ref-type="table-fn"}13 (9%)47 (12%)0.331*HFE* rs1799945 G allele[a](#tf0005){ref-type="table-fn"}34 (23%)115 (29%)0.136*TF* rs1049296 T allele[a](#tf0005){ref-type="table-fn"}26 (17%)117 (29%)0.005[^1][^2][^3][^4]

The proportions of risk allele carriers of rs1800562 (C282Y) and rs1799945 (H63D) were similar between the two study groups (p = 0.331 and p = 0.136); however, MS patients had a significantly increased frequency of rs1049296 T allele carriers (TF-C2; 17% vs. 29%, p = 0.005). There were no significant differences in demographic characteristics between risk-allele carriers and non-carriers.

3.2. Voxel based analysis {#s0060}
-------------------------

[Fig. 1](#f0005){ref-type="fig"} shows the regions with significantly different susceptibility values between MS patients with non-carrier alleles and HCs when using TFCE. MS patients had a statistically significant higher susceptibility in the putamen and caudate, especially in the right hemisphere (p \< 0.05). Thalamic susceptibility was significantly lower in MS patients, predominantly in the medial pulvinar nucleus of the thalamus. VBA analysis of the C282Y, H63D, and C2 gene variants did not reveal strong effects, although findings were significant in analyses without TFCE-FWE adjustments (see Supplement 1 and [Supplement Fig. 1](#f0015){ref-type="graphic"}).

To further investigate the relationship between allele status and study group effects, stratified GLM analyses were carried out.Fig. 1Results of the Voxel Based Analysis (VBA) for non-carrier MS patients vs. controls shown in the (a) axial, (b) coronal, and (c) sagittal plane. Shown are voxels with a p-value below 0.05 after FWE correction with TFCE in selected slices. Red indicates voxels where MS \> HC (putamen; p \< 0.05), blue indicates voxels where HC \> MS (thalamus, medial pulvinar nucleus; p \< 0.05). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 1.

### 3.2.1. Main effects of study groups, age, sex, and carrier status on magnetic susceptibility {#s0065}

Hemispheric differences of susceptibility were observed in region of interest (ROI) analyses of the thalamus (right + 1.4 ppb, p \< 0.001), putamen (right + 2.8 ppb, p \< 0.001), and pallidus (right + 2.5 ppb, p \< 0.001), but not the caudate (right − 0.5 ppb, p = 0.301). Subsequent analyses were split by hemisphere for the thalamus, putamen and pallidus.

Main effects of study group are presented in Supplement Table 1. MS patients had higher susceptibility than HC in the caudate (+ 7.5 ppb, p \< 0.001), left and right putamen (left: + 2.9 ppb, p = 0.042; right: + 4.2 ppb, p = 0.007) and left and right pallidus (left: + 14.8 ppb, p \< 0.001; right: + 15.1 ppb, p \< 0.001), while left and right thalamus susceptibility was markedly lower in MS (left: − 6.8 ppb, p \< 0.001; right: − 6.1 ppb, p \< 0.001). Compared to RRMS, progressive patients had higher susceptibility in the caudate (+ 2.7 ppb, p = 0.026), right putamen (+ 4.4 ppb, p = 0.011), right pallidus (+ 6.4 ppb, p = 0.029), and lower susceptibility in the bilateral thalamus (left: − 3.1 ppb, p = 0.002; and right: − 2.7 ppb, p = 0.009).

Using the total sample, iron risk allele status was not associated with change in susceptibility, except for H63D carriers having higher left and right putamen susceptibility (left: + 4.0 ppb, p = 0.006 and right: + 3.5 ppb, p = 0.024). Within both HC and MS, age was associated with susceptibility (between r = 0.170--0.430, p \< 0.05), except in the right thalamus of HCs (r = − 0.147, p = 0.074, likely due to a non-linear age progression of thalamic susceptibility). Sex differences were observed in the caudate (HC: 3.6 ppb, p = 0.043 and MS: + 5.5 ppb, p \< 0.001), with men having higher susceptibility. All significant main effects, except sex differences within HCs, remained after adjusting for FDR (q \< 0.05).

### 3.2.2. Magnetic susceptibility and carrier status stratified by group {#s0070}

To investigate possible interaction effects, stratified analyses were carried out. Within controls, C282Y risk allele carriers had higher right-sided putamen susceptibility (+ 6.1 ppb, *d* = 0.53, p = 0.040; [Table 2](#t0010){ref-type="table"}), although significance was lost after FDR correction. Similarly, HC H63D carriers had higher right putamen susceptibility (+ 6.7 ppb, *d* = 0.44, p = 0.039). Within MS, an effect was observed in the left putamen (+ 3.2 ppb, *d* *=* *0*.21, p = 0.040). All group-wise analyses, except some of the comparisons within the putamen, yielded significant results indicating differences between controls and MS patients (p \< 0.05, q \< 0.05; [Table 2](#t0010){ref-type="table"}).Table 2Mean magnetic susceptibility (in ppb) of risk allele carriers and non-carriers among healthy controls and patients with multiple sclerosis.Table 2.*HFE* rs1800562 (C282Y)HCMSOverall p-valueNon-carrierCarrierp-value (*d*)Non-carrierCarrierp-value (*d*)T ThalamusL Thalamus− 1.4 (7.0)0.5 (6.9)0.637 (0.27)− 7.8 (9.3)− 9.6 (10.6)0.163 (0.18)**\< 0.001**[⁎](#tf0020){ref-type="table-fn"}, [†](#tf0025){ref-type="table-fn"}R Thalamus− 0.4 (7.1)2.8 (7.3)0.173 (0.44)− 6.2 (9.3)− 7.7 (10.8)0.235 (0.15)**\< 0.001**[⁎](#tf0020){ref-type="table-fn"}, [†](#tf0025){ref-type="table-fn"}T Caudate36.7 (10.1)35.6 (9.8)0.650 (0.11)44.9 (11.7)43.0 (12.1)0.463 (0.16)**\< 0.001**[⁎](#tf0020){ref-type="table-fn"}, [†](#tf0025){ref-type="table-fn"}L CaudateR CaudateT PutamenL Putamen46.1 (14.6)51.3 (14.1)0.073 (0.36)50.2 (15.5)48.9 (13.9)0.730 (0.09)0.121R Putamen47.7 (15.9)53.8 (3.3)**0.040**[⁎](#tf0020){ref-type="table-fn"}**(0.53)**53.7 (16.2)51.1 (15.1)0.388 (0.17)**0.010**[⁎](#tf0020){ref-type="table-fn"}, [†](#tf0025){ref-type="table-fn"}T PallidusL Pallidus112.5 (22.1)109.1 (23.9)0.754 (0.15)127.6 (25.5)124.8 (27.0)0.586 (0.11)**\< 0.001**[⁎](#tf0020){ref-type="table-fn"}, [†](#tf0025){ref-type="table-fn"}R Pallidus104.3 (21.9)103.2 (14.0)0.999 (0.06)119.8 (26.7)117.9 (25.6)0.717 (0.07)**\< 0.001**[⁎](#tf0020){ref-type="table-fn"}, [†](#tf0025){ref-type="table-fn"}  *HFE* rs1799945 (H63D)HCMSOverall p-valueNon-carrierCarrierp-value (*d*)Non-carrierCarrierp-value (*d*)T ThalamusL Thalamus− 0.5 (7.0)− 3.1 (6.9)0.063 (0.37)− 7.7 (9.2)− 8.6 (10.0)0.317 (0.09)**\< 0.001**[⁎](#tf0020){ref-type="table-fn"}, [†](#tf0025){ref-type="table-fn"}R Thalamus− 0.1 (7.3)− 0.2 (6.4)0.944 (0.01)− 6.2 (8.7)− 6.6 (11.0)0.622 (0.04)**\< 0.001**[⁎](#tf0020){ref-type="table-fn"}, [†](#tf0025){ref-type="table-fn"}T Caudate36.1 (8.9)38.3 (12.9)0.393 (0.20)44.3 (12.0)45.3 (11.2)0.346 (0.09)**\< 0.001**[⁎](#tf0020){ref-type="table-fn"}, [†](#tf0025){ref-type="table-fn"}L CaudateR CaudateT PutamenL Putamen45.3 (14.7)50.9 (13.5)0.058 (0.40)49.1 (14.9)52.3 (15.8)**0.040**[⁎](#tf0020){ref-type="table-fn"} (0.21)**0.020**[⁎](#tf0020){ref-type="table-fn"}, [†](#tf0025){ref-type="table-fn"}R Putamen46.7 (15.4)53.6 (15.9)**0.039**[⁎](#tf0020){ref-type="table-fn"}**(0.44)**52.7 (16.2)54.8 (15.7)0.213 (0.13)**0.010**[⁎](#tf0020){ref-type="table-fn"}, [†](#tf0025){ref-type="table-fn"}T PallidusL Pallidus112.4 (22.4)110.5 (21.5)0.639 (0.09)126.4 (24.8)128.7 (27.1)0.639 (0.09)**\< 0.001**[⁎](#tf0020){ref-type="table-fn"}, [†](#tf0025){ref-type="table-fn"}R Pallidus103.5 (20.9)104.6 (21.9)0.701 (0.05)119.3 (26.9)119.2 (25.4)0.993 (0.01)**\< 0.001**[⁎](#tf0020){ref-type="table-fn"}, [†](#tf0025){ref-type="table-fn"}  *TF* rs1049296 (TF-C2)HCMSOverall p-valueNon-carrierCarrierp-value (*d*)Non-carrierCarrierp-value (*d*)T ThalamusL Thalamus− 1.5 (7.3)0.1 (5.9)0.100 (0.24)− 8.3 (9.5)− 7.0 (9.1)0.245 (0.14)**\< 0.001**[⁎](#tf0020){ref-type="table-fn"}, [†](#tf0025){ref-type="table-fn"}R Thalamus− 0.1 (7.3)− 1.1 (6.8)0.708 (0.14)− 6.5 (9.1)− 6.0 (9.8)0.679 (0.05)**\< 0.001**[⁎](#tf0020){ref-type="table-fn"}, [†](#tf0025){ref-type="table-fn"}T Caudate37.5 (10.8)35.8 (9.5)0.175 (0.1)44.0 (10.7)45.6 (11.6)0.571 (0.14)**\< 0.001**[⁎](#tf0020){ref-type="table-fn"}, [†](#tf0025){ref-type="table-fn"}L CaudateR CaudateT PutamenL Putamen48.1 (15.4)44.6 (13.7)0.069 (0.24)50.1 (15.8)50.4 (13.3)0.963 (0.02)0.285R Putamen49.9 (16.8)46.6 (12.8)0.117 (0.22)52.9 (16.2)53.9 (14.5)0.542 (0.07)0.089T PallidusL Pallidus112.0 (21.4)113.7 (23.7)0.927 (0.08)128.2 (26.3)124.3 (23.6)0.154 (0.16)**\< 0.001**[⁎](#tf0020){ref-type="table-fn"}^,†^R Pallidus103.5 (21.4)108.5 (18.3)0.734 (0.25)120.4 (27.8)116.5 (26.5)0.220 (0.14)**\< 0.001**[⁎](#tf0020){ref-type="table-fn"}^,†^[^5][^6][^7][^8]

Volumetric comparisons are presented in Supplement Material 2 and Supplement Table 2. To determine whether the observed susceptibility differences of HCs in the left (H63D) and right (C282Y and H63D) putamen ([Table 2](#t0010){ref-type="table"}) were independent from volumetric effects, structural volume was added as covariate. Effects remained significant after this correction ([Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}).Table 3Mean magnetic susceptibility (in ppb) of risk allele carriers and non-carriers among relapsing remitting and progressive MS patients.Table 3.*HFE* rs1800562 (C282Y)RelapsingProgressiveOverall p-valueNon-carrierCarrierp-value (*d*)Non-carrierCarrierp-value (*d*)T ThalamusL Thalamus− 6.8 (8.4)− 7.2 (10.9)0.751 (0.04)− 9.5 (10.4)− 14.8 (10.3)**0.043**^⁎^**(0.56)**0.108R Thalamus− 5.5 (8.7)− 4.6 (9.3)0.654 (0.10)− 7.4 (10.2)− 14.1 (11.3)**0.007**^⁎^**(0.62)0.021**^⁎^T Caudate43.9 (11.7)41.8 (12.4)0.384 (0.17)46.4 (11.7)45.5 (11.4)0.803 (0.08)0.690L CaudateR CaudateT PutamenL Putamen48.9 (14.9)48.3 (14.2)0.930 (0.04)52.3 (16.4)50.2 (13.8)0.796 (0.14)0.965R Putamen52.2 (15.1)49.1 (14.0)0.354 (0.21)56.3 (17.8)55.2 (16.8)0.886 (0.06)0.788T PallidusL Pallidus126.1 (22.9)121.4 (22.7)0.299 (0.21)130.2 (29.3)132.0 (34.3)0.777 (0.06)0.735R Pallidus118.0 (24.7)115.2 (24.2)0.618 (0.11)123.0 (29.5)123.8 (28.2)0.895 (0.03)0.954  *HFE* rs1799945 (H63D)RelapsingProgressiveOverall p-valueNon-carrierCarrierp-value (*d*)Non-carrierCarrierp-value (*d*)T ThalamusL Thalamus− 6.2 (8.7)− 7.6 (8.8)0.209 (0.16)− 10.1 (9.5)− 10.7 (12.4)0.691 (0.05)0.298R Thalamus− 5.3 (8.1)− 5.1 (9.6)0.811 (0.02)− 7.7 (9.4)− 9.7 (13.9)0.265 (0.17)0.415T Caudate\
L Caudate\
R Caudate43.1 (11.8)44.7 (11.8)0.238 (0.14)46.4 (12.3)46.5 (10.1)0.946 (0.01)0.466T PutamenL Putamen47.3 (13.4)52.3 (16.4)**0.013**^⁎^ (0.33)52.0 (16.7)52.9 (14.6)0.816 (0.06)0.131R Putamen50.6 (14.5)54.2 (15.4)0.079 (0.24)56.2 (18.1)56.1 (16.5)0.902 (0.01)0.425T PallidusL Pallidus124.9 (22.7)125.3 (22.6)0.862 (0.02)128.7 (27.8)135.8 (34.4)0.200 (0.23)0.440R Pallidus116.7 (25.0)117.7 (23.0)0.896 (0.04)123.5 (29.3)122.7 (30.7)0.902 (0.03)0.939  *TF* rs1049296 (TF-C2)RelapsingProgressiveOverall p-valueNon-carrierCarrierp-value (*d*)Non-carrierCarrierp-value (*d*)T ThalamusL Thalamus− 7.1 (8.9)− 5.9 (7.6)0.213 (0.15)− 10.5 (10.1)− 9.0 (10.9)0.523 (0.14)0.266R Thalamus− 5.5 (8.2)− 4.9 (9.1)0.535 (0.07)− 8.3 (10.4)− 7.9 (10.6)0.872 (0.04)0.525T Caudate42.8 (11.8)45.6 (11.1)0.285 (0.24)46.4 (11.8)45.8 (10.1)0.598 (0.05)0.511L CaudateR CaudateT PutamenL Putamen48.5 (15.2)49.9 (12.7)0.616 (0.10)53.0 (16.6)51.0 (14.5)0.617 (0.13)0.913R Putamen51.2 (15.2)52.8 (13.4)0.453 (0.11)56.3 (17.9)55.9 (16.2)0.888 (0.02)0.904T PallidusL Pallidus126.5 (23.8)121.7 (19.9)0.079 (0.22)131.2 (30.4)128.6 (28.6)0.668 (0.09)0.410R Pallidus118.1 (25.9)114.9 (21.2)0.414 (0.14)124.8 (30.7)119.3 (25.6)0.344 (0.19)0.582[^9][^10][^11][^12]

### 3.2.3. Magnetic susceptibility associated with carrier status stratified by MS type {#s0075}

Analyses stratified by MS type are shown in [Table 3](#t0015){ref-type="table"}. Within progressive MS, C282Y risk-allele carriers had lower thalamic susceptibility (left: − 5.3 ppb, *d* = 0.56, p = 0.043, right − 6.7 ppb, *d* = 0.62, p = 0.007, [Fig. 2](#f0010){ref-type="fig"}), an effect that remained significant after adjusting for thalamic volume. Additionally, left putamen susceptibility was higher among relapsing H63D risk-allele carriers (+ 5 ppb, *d* = 0.33, p = 0.047). Adjustment for FDR resulted in loss of significance.Fig. 2Distribution of thalamic susceptibility by rs1800562 allele status between HC, RR and Progressive MS. The evolution from HC to RR to progressive MS in thalamic susceptibility reduction is apparent. The C282Y mutation is linked to reduced bilateral thalamus susceptibility within progressive MS. Data is presented as mean ± standard error. \*p \< 0.05, \*\*p \< 0.01.Fig. 2.

### 3.2.4. Susceptibility between male and female MS patients stratified by carrier status {#s0080}

Women had consistently lower susceptibility in the caudate and putamen (*d* = 0.26--0.59, p \< 0.001--0.049), but only among patients who did not carry risk alleles, regardless of SNP ([Table 4](#t0020){ref-type="table"}). Male risk-allele carriers had similar, or slightly lower (higher for thalamus), susceptibilities as compared to male non-carriers (all p ≥ 0.120). Female risk-allele carriers, however, had overall higher (lower for thalamus) susceptibilities than female non-carriers (H63D carriers vs. non-carriers: left putamen p = 0.024, right putamen p = 0.010, all others p ≥ 0.071), bringing them in line with males. Female *TF*-C2 risk-allele carriers had even lower left thalamic susceptibility than their male carrier counterparts (*d* = 0.35, p = 0.042). Caudal susceptibility differences between men and women non-carriers remained significant after FDR correction (q \< 0.05).Table 4Mean magnetic susceptibility (in ppb) of men and women and risk allele carriers and non-carriers among patients with multiple sclerosis.Table 4.*HFE* rs1800562 (C282Y)Allele non-carriersAllele carriersOverall p-valueMenWomen (n = 213)p-value (*d*)Men (n = 15)Womenp-value (*d*)T ThalamusL Thalamus− 7.7 (8.1)− 7.9 (9.9)0.676 (0.02)− 7.3 (7.5)− 10.7 (11.8)0.182 (0.34)0.259R Thalamus− 5.8 (8.2)− 6.5 (9.8)0.251 (0.08)− 4.4 (8.1)− 9.2 (11.7)0.105 (0.48)0.114T Caudate48.7 (10.7)42.8 (11.7)**\< 0.001**[⁎](#tf0040){ref-type="table-fn"}, [†](#tf0045){ref-type="table-fn"}**(0.53)**44.4 (9.8)42.3 (13.1)0.744 (0.18)**0.001**[⁎](#tf0040){ref-type="table-fn"}, [†](#tf0045){ref-type="table-fn"}L CaudateR CaudateT PutamenL Putamen53.1 (15.8)48.7 (14.2)**0.025**[⁎](#tf0040){ref-type="table-fn"} (0.29)48.0 (14.2)49.3 (14.0)0.646 (0.09)0.152R Putamen56.1 (16.7)52.4 (15.9)0.061 (0.23)51.6 (16.6)50.8 (14.6)0.938 (0.05)0.243T PallidusL Pallidus128.1 (25.9)127.3 (25.3)0.971 (0.03)116.8 (26.1)128.5 (27.0)0.101 (0.44)0.401R Pallidus120.5 (27.3)119.5 (26.4)0.862 (0.04)111.9 (23.4)120.7 (26.4)0.162 (0.35)0.647  *HFE* rs1799945 (H63D)Allele non-carriersAllele carriersOverall p-valueMenWomenp-value (*d*)MenWomenp-value (*d*)T ThalamusL Thalamus− 7.6 (7.9)− 7.8 (9.8)0.739 (0.02)− 8.3 (8.3)− 8.9 (10.9)0.440 (0.06)0.641R Thalamus− 5.8 (7.9)− 6.5 (9.1)0.348 (0.08)− 5.6 (8.9)− 7.1 (12.1)0.204 (0.14)0.422T Caudate48.2 (10.6)42.2 (12.3)**\< 0.001**[⁎](#tf0040){ref-type="table-fn"}, [†](#tf0045){ref-type="table-fn"}**(0.52)**48.3 (10.7)43.6 (11.3)0.111 (0.43)**0.001**[⁎](#tf0040){ref-type="table-fn"}, [†](#tf0045){ref-type="table-fn"}L CaudateR CaudateT PutamenL Putamen51.6 (15.1)47.7 (14.6)**0.049**[⁎](#tf0040){ref-type="table-fn"} (0.26)54.3 (16.3)51.2 (15.6)0.670 (0.19)**0.046**[⁎](#tf0040){ref-type="table-fn"}R Putamen55.7 (17.3)51.1 (15.4)**0.027**[⁎](#tf0040){ref-type="table-fn"} (0.28)55.2 (15.1)54.6 (16.2)0.686 (0.04)0.094T PallidusL Pallidus127.6 (25.9)125.7 (24.2)0.758 (0.08)125.7 (26.2)130.2 (27.7)0.238 (0.17)0.425R Pallidus121.1 (27.9)118.3 (26.3)0.508 (0.10)115.3 (24.3)121.4 (25.9)0.145 (0.36)0.413  *HFE* rs1049296 (TF-C2)Allele non-carriersAllele carriersMenWomenp-value (*d*)MenWomenp-value (*d*)Overall p-valueT ThalamusL Thalamus− 9.2 (7.7)− 7.8 (10.2)0.433 (0.15)− 5.3 (8.0)− 8.4 (9.6)**0.042**[⁎](#tf0040){ref-type="table-fn"} (0.35)0.136R Thalamus− 5.9 (7.6)− 6.8 (9.8)0.246 (0.10)− 5.9 (9.1)− 6.1 (10.3)0.707 (0.02)0.623T Caudate48.6 (10.8)41.9 (11.9)**\< 0.001**[⁎](#tf0040){ref-type="table-fn"}, [†](#tf0045){ref-type="table-fn"}**(0.59)**47.6 (10.5)43.9 (10.7)0.129 (0.35)**\< 0.001**[⁎](#tf0040){ref-type="table-fn"}, [†](#tf0045){ref-type="table-fn"}L CaudateR CaudateT PutamenL Putamen53.9 (16.6)48.2 (15.2)**0.014**[⁎](#tf0040){ref-type="table-fn"} (0.36)49.5 (12.4)51.1 (14.1)0.480 (0.12)0.070R Putamen56.6 (17.3)51.2 (15.6)**0.020**[⁎](#tf0040){ref-type="table-fn"} (0.33)53.5 (14.4)54.3 (14.6)0.630 (0.06)0.100T PallidusL Pallidus130.3 (26.5)127.1 (26.2)0.539 (0.12)120.1 (23.5)127.7 (23.1)0.068 (0.33)0.129R Pallidus121.8 (29.5)119.7 (27.1)0.741 (0.07)113.9 (19.6)118.7 (25.2)0.222 (0.21)0.452[^13][^14][^15][^16]

3.3. Association of EDSS with allele presence {#s0085}
---------------------------------------------

Within progressive MS, C282Y carriers had significantly higher EDSS scores (mean = 5.5, median = 6.0, IQR = 4.0--6.5 vs. mean = 6.5, median = 6.5, IQR = 5.75--7.5, p = 0.027). Other genotypes were not correlated with EDSS.

4. Discussion {#s0090}
=============

This is one of the first studies investigating the effects of common genetic variants associated with iron regulation and metabolism (*HFE* C282Y, H63D, and *TF*-C2) on in vivo deep GM measurements in HCs and MS. Of the investigated SNPs, we only observed a higher prevalence of *TF*-C2 in MS patients. Magnetic susceptibility differences between genetic risk carriers vs. non-carriers were mainly observed in our healthy population (with higher susceptibility in the putamen) and progressive MS patients (with lower susceptibility in the thalamus). Interestingly, sex differences were observed not in patients with the risk allele, but among patients with wild-type status.

4.1. Main effects of magnetic susceptibility {#s0095}
--------------------------------------------

As has been extensively reported ([@bb0110], [@bb0370], [@bb0150]), deep GM iron levels are thought to be disturbed in MS. In MS, T~2~ hypointensity, R~2~\*, and susceptibility-weighted phase imaging are correlated with structural damage ([@bb0060], [@bb0385]), advancing MS disease course ([@bb0155], [@bb0070]), and with physical and cognitive measures of disability ([@bb0075], [@bb0080], [@bb0165], [@bb0230]). This study used a recently developed advanced MR imaging technique (QSM) ([@bb0265], [@bb0315]), allowing the measurement of subtle changes of the magnetic susceptibility of tissue. QSM is regarded as one of the most sensitive and specific techniques for studying tissue iron in vivo in MS ([@bb0215], [@bb0345]).

Although not the primary aim of the present work, in line with previous reports, we observed significant disease group effects in both VBA and ROI analyses: MS patients had higher susceptibility in the caudate, putamen and pallidus compared to controls. Progressive MS patients had higher values in the caudate, right putamen, and left pallidus compared to RRMS. As was recently reported using QSM ([@bb0175], [@bb0320]), thalamic susceptibility was lower in RRMS (vs HC) and progressive patients (vs RRMS). Decreased thalamic iron concentrations are known to occur in normal aging ([@bb0185], [@bb0175]), and is likely a product of physically reduced iron levels, and in MS, due to myelin changes, and/or potentially even deposition of insoluble calcium phosphate ([@bb0300], [@bb0305], [@bb0175]).

VBA analysis showed the decreased thalamic susceptibility effect to be mostly contained to the pulvinar of the thalamus, a finding opposite to other reports which generally observe increased pulvinar iron levels (e.g. ([@bb0155], [@bb0385], [@bb0015], [@bb0290])). It may be that increased pulvinar susceptibility is found predominantly in younger patients (\< 40 years) whereas in older patients, as is the case in this study, pulvinar susceptibility has decreased below that in controls ([@bb0320]). A reduction in thalamic susceptibility points to a reduction in iron concentration, possibly from iron being released from oligodendrocytes as a result of chronic microglia activation ([@bb0375]).

4.2. Iron genes and magnetic susceptibility in healthy controls {#s0100}
---------------------------------------------------------------

Three SNPs known to be associated with iron disruption were quantified: *HFE* rs1800562 (C282Y) and *HFE* rs1799945 (H63D), associated with hereditary hemochromatosis, and rs1049296 (TF-C2), associated with iron transport. Mutations were observed less frequently in HC than MS, with genotype frequency being highly comparable to other reports. In a large population-based study comprising 5171 subjects ([@bb0330]), the C282Y genotype had a prevalence of 8.6% (9% in the present study), and H63D had a prevalence of 23.3% (23% in the present study). The *TF*-C2 allele frequency varies widely depending on the population under study, but ranges between 9 and 20% in European samples ([@bb0050]). *TF*-C2 frequency in our study was 17%, with our sample consisting of approximately 80% Caucasians. These findings indicate that the HCs investigated are representative and that observations of deep GM magnetic susceptibility can be generalized to a larger population.

No differences in magnetic susceptibility were observed after correction for FDR. However, without FDR correction, HCs with the H63D mutation had significantly higher right putamen susceptibility than those without. Concurrently, putamen volume was markedly lower in subjects who were H63D carriers. After adjusting for structural volume, right putamen susceptibility remained significantly higher among risk allele carriers (p \< 0.05). As such, it stands to reason that the H63D gene variant is associated with an increase of iron in the right putamen of HCs. Further unadjusted differences were observed in right putamen susceptibility and volume (C282Y) and thalamus volume (H63D) of HCs. Bartzokis et al. ([@bb0035]) has previously revealed significantly higher brain iron in the caudate nucleus of older men (≥ 55 years) who had at least one iron gene mutation. Caudate magnetic susceptibility nor volume reached significance in the present study. Another recent study investigated a range of factors possibly linked to brain iron changes in the normal aging brain using R2\*, including genetic predisposition ([@bb0250]). In contrast to the present study (where a putamen x gene effect was observed) and Bartzokis et al. ([@bb0035]) (where a caudate x gene effect was observed), they did not report any effect of the C282Y, H63D or *TF*-C2 mutation. It has to be noted that, as in Bartzokis et al., Pirpamer et al. report a substantially older sample (mean age: 65.4 years) when compared to the present study (mean age: 45.6 years). Potential gene effects may manifest at different ages, especially considering deep GM iron levels are known change at different trajectories depending on region and age ([@bb0185]).

4.3. Iron genes and magnetic susceptibility in multiple sclerosis {#s0105}
-----------------------------------------------------------------

To our knowledge, this is one of the first studies investigating genes coding for iron functioning in MS in the context of iron-sensitive brain MRI. MS patients with the H63D mutation had increased left putamen susceptibility (+ 3.2 ppb). No other region showed susceptibility or volume differences between carriers and non-carriers. Subsequent analysis of relapsing and progressive MS patients showed a differing picture for each group. RRMS patients retained the uncorrected effect of H63D in the left putamen that was observed in the MS group as a whole, while progressive patients who had the C282Y gene variant had substantially lower susceptibility in the bilateral thalamus (\>− 5.3 ppb, *d* \> 0.56), indicating lower thalamic iron. Regardless of genotype, progressive patients had lower thalamic susceptibility than relapsing patients, who in turn had lower susceptibilities than HCs. In line with our study, a recent report found lower thalamic susceptibility in RRMS patients, compared to HCs ([@bb0085]). They also observed an increase in susceptibility for (primary) progressive MS. This apparent discrepancy may be explained by the present study including secondary-progressive patients and Burgetova\'s sex ratio being substantially different (female/male: 0.7 vs. 1.8 in the present study).

Few studies have investigated iron associated genetic mutations in MS. Ristic et al. ([@bb0275]) investigated prevalence rates of genes associated with hereditary hemochromatosis and found a similar rate of C282Y and H63D mutations between controls and MS, and did not observe increased disease progression among carriers. Earlier disease onset in patients carrying the C282Y mutant allele, however, was observed ([@bb0275]). Also, although not statistically significant, EDSS scores were higher in patients heterozygous for H63D (EDSS: 4.7 ± 2.5) and C282Y (EDSS: 5.0 ± 1.8) compared to MS patients with wild-type alleles (EDSS: 4.3 ± 2.4). Rubio et al. ([@bb0285]) reported an increased frequency of the *HFE* C282Y mutation in MS compared to HC (10.2% vs. 6.7%). A more recent study investigating the association of iron related polymorphisms in MS found an increased Multiple Sclerosis Severity Score (MSSS) and disease progression in H63D-, but not among C282Y- carriers ([@bb0140]). Presence of any iron risk polymorphism under investigation (H63D, C282Y, and others vs. wild-type) was associated with higher EDSS, MSSS, and progression scores. In the present study, mutations in the *HFE* gene (C282Y & H63D) were not significantly more present in MS patients, although frequencies were overall higher. The transferrin mutation (TF-C2) did occur more frequently (29% vs. 17%) in patients. Within progressive MS, only C282Y was associated with higher EDSS scores. This moderate association of EDSS with genotype is in line with Ristic et al. ([@bb0275]). However, we observed no difference in MS disease onset between carriers and non-carriers.

4.4. Iron genes and sex differences in multiple sclerosis {#s0110}
---------------------------------------------------------

We have previously reported that women had an accelerated putamen susceptibility trajectory over age as compared to men among healthy subjects ([@bb0160]). In contrast to this finding, but in line with the present study, Bartzokis et al. ([@bb0025], [@bb0030]) showed increased brain iron in men compared to women and suggested that brain iron levels could contribute to earlier disease onset of neurodegenerative disorders in men. Persson et al. ([@bb0245]) reported lower substantia nigra susceptibility in women and a distinct plateauing effect specifically in the pulvinar nucleus of only women. Interestingly, women who were postmenopausal had lower levels of iron deposition, even after adjusting for the effects of aging ([@bb0245]). Overall, it appears sex may influence brain iron status due to several factors including sex hormones, menopause and menstruation. The influence of genetic risk factors and sex differences are less clear, however. Bartzokis et al. ([@bb0040]) report that the association of brain iron and cognition was influenced by sex and genetic variation independently, i.e. they observed a strong association of (i) verbal memory function and hippocampal iron in men, and (ii) working memory function with basal ganglia iron among solely wild-type *HFE* and *TF* gene carriers, regardless of gender. Evidently, there are specific sex and gene effects regarding deep GM iron levels. In the present study we did not investigate cognitive functioning. However, within MS patients, distinct sex effects were observed in the susceptibility of the caudate and putamen, but, similar to Bartzokis et al., most effects were only apparent in wild-type gene carriers. Female non-carriers presented with lower susceptibilities than men, while average susceptibilities among participants with the C282Y, H63D, or C2 mutation were similar between men and women; with male carriers having the same or lower susceptibilities, and female carriers having higher susceptibilities than their non-risk allele carrying counterparts. One potential explanation could be a group difference between the number of women who have reached menopause. Even though we did not record menopause status among women, female MS patients with genetic mutations were of similar age to those without (mean age 46.0 ± 12.1 vs. 46.4 ± 10.8 years), making a group difference in number of women who are postmenopausal unlikely. Therefore, it may be that specifically within female MS patients, having any of the *HFE* or *TF* risk alleles could increase iron levels to a similar level as men. Our results are in line with the observation that women tend to have lower susceptibilities in the deep GM than men ([@bb0030]). Genetic mutations of iron-related genes may be a risk factor for women with respect to brain iron measurements; conversely, being a gene carrier male MS patient may be immaterial or even somewhat protective. Although only indirectly related to this, it is interesting to note that Bathum et al. ([@bb0045]) reported that the C282Y genetic variant frequency reduces with age, suggesting carriers have a decreased life expectancy; this finding was specific to women. In addition, as men with MS tend to have poorer outcomes and progress more rapidly than women ([@bb0350]), further research into genetic variation among women will have to be conducted to elucidate to what extent disease course is influenced.

4.5. Limitations {#s0115}
----------------

Although the frequency of genetic variation is in line with previous reports ([@bb0330]), some of the investigated study groups were limited in size, especially in the smaller HC sample (e.g. n = 13 C282Y allele carriers in HCs). Further, because of limited sample size we did not investigate any interaction effects of sex with genotype within HCs. While limited statistical power was less of an issue in the MS group, sub-analyses within disease type and sex were carried out using smaller samples. Both unadjusted and adjusted (FDR) p-values are reported to both maximize power and minimize false negative and positive findings. Irrespective of statistical power to detect significance, effect sizes were reported, and VBA analyses were carried out using all participants. Future studies employing larger sample sizes are warranted.

ROI-based analysis was employed in this and many other studies investigating susceptibility in MS. The FSL FIRST method may introduce disease-related anatomical bias due to brain abnormalities, although inaccuracies are likely to stem from poor transformation to MNI space ([@bb0130]), suggesting inaccuracies manifest randomly. Furthermore, tissue pathology may be restricted to certain anatomical sub-regions ([@bb0320]), such as the pulvinar, as was observed previously ([@bb0385], [@bb0170]) and in this study using VBA.

Magnetic susceptibility may be influenced by factors other than iron, including changes in myelin or atrophy of tissue compartments with little iron. In the present study, susceptibility values were referenced to the whole brain average susceptibility, whereas several authors have utilized differing reference regions, e.g. the internal capsule ([@bb0335]) and frontal deep white matter ([@bb0115]). The choice of reference region has substantial impact on the results due to pathology-related changes in the reference regions. In our view, the whole brain average represents the best trade-off between susceptibility anisotropy effects, localized artifacts, and pathology related susceptibility changes ([@bb0175]).

4.6. Conclusion {#s0120}
---------------

In conclusion, we sought to investigate whether iron linked genetic polymorphisms were associated with deep GM susceptibility, and thereby may have an influence on brain iron levels. Our findings moderately support this notion: differences were observed between genetic risk allele carriers and non-carriers, although some effects were lost to multiple comparison correction. Increased susceptibility, indicative of higher iron levels, was observed in C282Y and H63D allele carriers in the right putamen of HCs, and left putamen of patients with MS (H63D). Bilateral thalamic iron susceptibility tended to be lower in progressive-, but not relapsing- MS patients with the C282Y mutation. Sex differences were apparent in MS patients; women with wild-type (but not mutation) gene status had lower magnetic susceptibilities than men, suggesting that iron-related risk alleles could be a risk factor for female MS patients. Further inquiry into the interaction of sex and genotype with brain iron is warranted.

The following are the supplementary data related to this article.Supplementary data.Image 1Supplementary Fig. 1Results of unadjusted Voxel Based Analysis (VBA) for the interaction between rs1800562 (C282Y) and disease group (multiple sclerosis/healthy controls). Shown results correspond to p \< 0.05, indicating susceptibility is modulated by both allele variance and disease status in the left putamen, pallidus, and medial pulvinar nucleus.Supplementary Fig. 1.
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[^1]: Note: n/a; not applicable; HC: healthy control; EDSS = Expanded Disability Status Scale. HFE = human hemochromatosis, TF = transferrin.

[^2]: Number of risk-allele carriers either heterozygous and homozygous. The number of heterogeneous carriers were: HC = 0, MS = 0 for rs1800562 A allele, HC = 6, MS = 11 for rs1799945 G allele, HC = 1, MS = 11 for rs1049296 T allele.

[^3]: Mean (SD) age of RRMS and progressive MS: 43.0 (10.1), 52.8 (7.7).

[^4]: SPMS: n = 102, PPMS: n = 37.

[^5]: Note: HC = Healthy Control; MS = Multiple Sclerosis; T = Total; L = Left; R = Right. p \< 0.05 and Cohen\'s *d* medium effect (\> 0.50) are bolded.

[^6]: Thalamus, putamen and pallidus analyses were carried out separately for the left and right hemisphere due to observed hemispheric differences.

[^7]: Remains significant (p \< 0.05) after adjusting for structural volume.

[^8]: Remains significant (q \< 0.05) after FDR correction by gene.

[^9]: Note: T = Total; L = Left; R = Right. p \< 0.05 and Cohen\'s *d* medium effect (\> 0.50) are bolded.

[^10]: Thalamus, putamen and pallidus analyses were carried out separately for the left and right hemisphere due to observed hemispheric differences.

[^11]: ^⁎^ Remains significant (p \< 0.05) after adjusting for structural volume.

[^12]: ^†^ Remains significant (q \< 0.05) after FDR correction by gene.

[^13]: Note: T = Total; L = Left; R = Right. p \< 0.05 and Cohen\'s *d* medium effect (\> 0.50) are bolded.

[^14]: Thalamus, putamen and pallidus analyses were carried out separately for the left and right hemisphere due to observed hemispheric differences.

[^15]: Remains significant (p \< 0.05) after adjusting for volume.

[^16]: Remains significant (p \< 0.05) after FDR correction by gene.
